Cytori Therapeutics (CYTX) Lifted to “Buy” at B. Riley

B. Riley upgraded shares of Cytori Therapeutics (NASDAQ:CYTX) from a neutral rating to a buy rating in a report issued on Friday morning. B. Riley also issued estimates for Cytori Therapeutics’ Q4 2017 earnings at ($0.10) EPS, FY2017 earnings at ($0.68) EPS, Q1 2018 earnings at ($0.06) EPS, Q2 2018 earnings at ($0.06) EPS and FY2018 earnings at ($0.18) EPS.

CYTX has been the topic of a number of other research reports. Zacks Investment Research downgraded Cytori Therapeutics from a hold rating to a sell rating in a research report on Thursday, November 9th. Maxim Group set a $2.00 price objective on Cytori Therapeutics and gave the stock a buy rating in a report on Friday. Laidlaw reiterated a buy rating and issued a $1.65 price objective on shares of Cytori Therapeutics in a report on Thursday, February 22nd. Finally, ValuEngine upgraded Cytori Therapeutics from a strong sell rating to a sell rating in a report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average price target of $1.80.

Shares of Cytori Therapeutics (NASDAQ CYTX) opened at $0.32 on Friday. Cytori Therapeutics has a 12-month low of $0.22 and a 12-month high of $2.08. The firm has a market capitalization of $11.41, a PE ratio of -0.37 and a beta of 3.49.

Cytori Therapeutics (NASDAQ:CYTX) last released its quarterly earnings results on Thursday, March 8th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.02). Cytori Therapeutics had a negative net margin of 418.36% and a negative return on equity of 235.58%. The firm had revenue of $1.50 million for the quarter, compared to analysts’ expectations of $2.00 million. analysts forecast that Cytori Therapeutics will post -0.18 earnings per share for the current fiscal year.

In other news, major shareholder Bank Sa Swissquote sold 100,000 shares of Cytori Therapeutics stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $0.38, for a total value of $38,000.00. Following the transaction, the insider now owns 5,496,655 shares in the company, valued at $2,088,728.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Ag Postfinance sold 236,155 shares of Cytori Therapeutics stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $0.34, for a total value of $80,292.70. Following the completion of the transaction, the insider now owns 5,311,451 shares in the company, valued at approximately $1,805,893.34. The disclosure for this sale can be found here. In the last quarter, insiders sold 695,767 shares of company stock worth $231,951. Company insiders own 1.90% of the company’s stock.

An institutional investor recently raised its position in Cytori Therapeutics stock. Vanguard Group Inc. lifted its stake in Cytori Therapeutics Inc (NASDAQ:CYTX) by 81.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 612,304 shares of the biotechnology company’s stock after buying an additional 275,653 shares during the period. Vanguard Group Inc. owned approximately 1.89% of Cytori Therapeutics worth $674,000 as of its most recent SEC filing. Institutional investors and hedge funds own 10.57% of the company’s stock.

WARNING: “Cytori Therapeutics (CYTX) Lifted to “Buy” at B. Riley” was originally published by Markets Daily and is the property of of Markets Daily. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply